TheChek News Flow

Jana Partners (Barry Rosenstein) discloses updated portfolio positions in 13F filing: New FIS position

Highlights from Q4 2022 filing as compared to Q3 2022:

• New positions in: FIS (~2.56 mln shares)
• Increased positions in: EHAB (to ~2.43 mln shares from ~1.96 mln shares)
• Maintained positions in: THS (~4.75 mln shares)
• Closed positions in: MNTV (from ~0.93 mln shares)
• Decreased positions in: EHC (to ~0.39 mln shares from ~2.63 mln shares), NEWR (to ~3.21 mln from ~3.53 mln), MRCY (to ~3.06 mln from ~3.34 mln), LH (to ~0.74 mln from ~0.92 mln), FRPT (to ~4.15 mln from ~4.27 mln), SPY (to ~0.12 mln from ~0.15 mln)

Gapping down
In reaction to earnings/guidance:

• OM -12.3% ANGI -5.6% SEDG -5.1% ENTG -4.9% GEO -4.2% AMKR -4% LCII -4% QSR -3.6% CLF -3.5% HWM -2.6% ES -1.9% MEDP -1.7% PKI -1.7% LDOS -1.7% DAVA -1.7% TRU -1.6% TRTN -1% INMD -0.9%

Other news:

• CISO -10% (stock offering)
• PRPL -3.1% (responds to Coliseum Capital Management)
• VIR -1.5% (amends collaboration with GSK)
• CPE -0.9% (Board Chair retiring; names new Chair)
• MGNX -0.8% (announces prelim results from study of Lorigerlimab)

Analyst comments:

• FSLR -2.6% (downgraded to In-line from Outperform at Evercore ISI)
• OKTA -1.4% (initiated with a Sell at Goldman)
• TTWO -0.9% (downgraded to Hold from Buy at DZ Bank)

Gapping up
In reaction to earnings/guidance:

• PLTR +18.3%, SKYT +9.4%, KULR +6% (Q4 guidance), EMBC +5.5%, BLKB +5%, IRBT +4.4%, CDNS +3.8%, NTB +3.2%, ZTS +3.2%, DENN +3%, KRG +2.7%, CAR +1.8%, GFS +1.6%, PAX +1.5%, ANET +1.4%, OTTR +1.3%, WCC +1.3%, KO +1.2%, IAC +1%, MAR +0.8%

Other news:

• FUSN +20.4% (acquires RadioMedix)
• AMLX +6% (will provide a corporate update including information on the commercial launch of RELYVRIO at upcoming conference)
• GRTS +4.1% (entered into a clinical trial agreement with the National Cancer Institute to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate SLATE-KRAS in a Phase 1 study)
• BTAI +3.5% (announces data from Phase 2 trial of BXCL701)
• KALV +3.1% (provides multiple clinical trial and regulatory updates for its lead compound sebetralstat as a potential oral on-demand therapy for HAE attacks)
• MCRB +3% (announces the publication of data from its Phase 3 ECOSPOR IV trial in JAMA Network Open that reinforce previously published results from the Phase 3 ECOSPOR III study on the investigational microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection)
• USNA +2.3% (CEO transitioning to Executive Chairman; new CEO named)
• SNDL +2% (reducing headcount)
• BCYC +1.8% (Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009)
• EQC +1.4% (declares special cash dividend)
• EGY +1.1% (raises dividend; provides operational update)

Analyst comments:

• FIS +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
• PANW +1.3% (initiated with a Buy at Goldman)
• OXY +1.1% (upgraded to Buy from Neutral at Goldman)
• FTNT +0.6% (initiated with a Buy at Goldman)

Early premarket gappers

• Gapping up:
  • PLTR +18.3%, FUSN +17.7%, SKYT +12%, CGEM +7.2%, KULR +6%, EQC +5.3%, BLKB +5%, CDNS +4.9%, WCC +4%, BTAI +3.5%, IAC +3.5%, NTB +3.2%, DENN +3%, KRG +2.7%, CAR +2.5%, LDOS +2%, EGY +1.7%, SNDL +1.5%, OTTR +1.3%, GEO +1.3%, PTRA +1.1%, AMK +0.9%, CTKB +0.8%
• Gapping down:
  • OM -11%, CISO -6.4%, ANGI -5.6%, SEDG -5.1%, INST -5%, VIR -3.4%, CLF -3.3%, AMKR -3.1%, PRPL -2.5%, MEDP -2.1%, ES -1.9%, CPE -1.3%, EQT -1%, MGNX -0.8%, IRBT -0.8%, LSCC -0.8%